Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of “Hold” by Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been given a consensus recommendation of “Hold” by the fourteen analysts that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $14.6923.

Several research analysts have weighed in on ARVN shares. Truist Financial set a $10.00 price target on shares of Arvinas in a research report on Wednesday, March 18th. Piper Sandler restated an “overweight” rating and issued a $20.00 price target (up from $16.00) on shares of Arvinas in a research report on Wednesday, February 25th. Citigroup raised their price objective on Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. Zacks Research downgraded Arvinas from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Finally, Wedbush increased their target price on shares of Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th.

Arvinas Price Performance

Shares of ARVN opened at $9.08 on Monday. The firm has a market capitalization of $585.84 million, a P/E ratio of -2.73 and a beta of 1.79. Arvinas has a one year low of $6.05 and a one year high of $14.51. The business has a fifty day moving average of $10.97 and a 200 day moving average of $11.67.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, May 12th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.05. The business had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $16.61 million. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The business’s revenue for the quarter was down 91.7% on a year-over-year basis. During the same period last year, the firm posted $1.14 earnings per share. Analysts expect that Arvinas will post -2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director John G. Houston sold 35,297 shares of Arvinas stock in a transaction on Friday, February 27th. The shares were sold at an average price of $13.21, for a total transaction of $466,273.37. Following the transaction, the director owned 1,122,183 shares in the company, valued at approximately $14,824,037.43. The trade was a 3.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Randy Teel sold 9,657 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $95,990.58. Following the completion of the sale, the chief executive officer owned 287,218 shares of the company’s stock, valued at $2,854,946.92. The trade was a 3.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 81,449 shares of company stock valued at $945,574. Insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On Arvinas

A number of hedge funds have recently made changes to their positions in ARVN. Tower Research Capital LLC TRC grew its position in shares of Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after purchasing an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after purchasing an additional 3,500 shares during the period. State of Wyoming purchased a new stake in Arvinas during the 3rd quarter valued at approximately $68,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Arvinas in the third quarter valued at $92,000. Finally, Jain Global LLC bought a new position in shares of Arvinas during the third quarter valued at approximately $95,000. Institutional investors own 95.19% of the company’s stock.

Arvinas News Summary

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a Buy rating, signaling continued Wall Street confidence in upside potential. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer’s breast cancer drug vepdegestrant was licensed to Rigel Pharmaceuticals in a deal that includes $85 million upfront and up to $320 million in milestones, which supports the value of Arvinas’ PROTAC platform and adds potential non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas’ breast cancer drug
• Neutral Sentiment: HC Wainwright modestly adjusted several earnings forecasts for Arvinas, including lower estimates for 2026-2029 and a small cut to FY2030 EPS, reflecting ongoing uncertainty around future profitability rather than a major new development.
• Neutral Sentiment: Arvinas recently beat Q1 EPS estimates, but revenue missed expectations and dropped sharply year over year, reinforcing that the company remains far from sustained profitability. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Recent insider selling by the CEO, CFO, CAO, and another executive may be pressuring sentiment, even though the sales were disclosed as tax-withholding transactions tied to equity vesting. CEO insider filing

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.